About Us

We provide standalone technical services for various stages of biological drug development and also end to end support for R&D from discovery to clinical studies. We focus on the establishment of a high quality integrated services platform to support global biopharmaceutical companies.

Mab-Venture was established in early 2014 in Shanghai's Zhangjiang Hi-Tech Park. It is a fully integrated biologics CRO/CDMO dedicated to the whole industry chain from research to commercialization. Mab-Venture is also committed to developing a biopharmaceutical research and development platform. In May 2015, Mab-Venture built a new 1700 sq.m. R&D and pilot production base in Shanghai's Zhangjiang International Medical Park. In March 2017, Mab-Venture built an additional 3350 sq.m. pilot production base. The two facilities provide an end-to-end solution to two pilot production lines to support biologics development and manufacture in the pre-clinical and early clinical stages. So far the company has built a strong R & D team with more than 100 people and invested over $20 million dollars on equipment.

Facing the increasingly fierce domestic competition of antibody drug development, Mab-venture's strategy is focusing on the biosimilar antibody service such as quality research, CMC process development, bioanalysis and IND. Mab-Venture competes in different area by making complimentary strategic cooperation with other CRO company.

Our mission is to create an efficient platform so that we can help our customers to commercialize their products with high quality, low cost, so it is affordable for patients, ultimately resolving major health problems in our lives.

In March 2020, Mab-Venture was awarded the certificate of Pudong New Area Enterprise R & D Institution.
In December 2019, Mab-Venture continued to win the honorary title of high-tech enterprise.
In March 2019, Mab-Venture joined the Innovative platform of Shanghai Science and Technology.
In Sep. 2018, Mab-Venture won the candidate of cultivation of Little Giant of Science and Technology.
In Sep. 2018, Mab-Venture won the funds for key technical innovative enterprise sponsored by Pudong Government.
In Apr. 2018, The IND of "Recombinant of fully humanized anti-CTLA-4 monoclonal antibody injection" was approve by NMPA, Mab-Venture and ShuangLu pharm contributed equally.
In 2018, Mab-Venture joined Shanghai Science and Technology Research Center.
In 2017,Mab-Venture certificated as Shanghai Specialized and innovative Start-up.
In 2016,Development and Commercialization of Innovative Monoclonal Antibody was awarded by Shanghai government, Innovation Funds for Start-up.
In 2016, Mab-Venture recognized as High-tech Enterprises.
In 2015,Development of a Kit for Detecting Drug Resistance of Monoclonal Antibody in Autoimmune Diseases was supported by Shanghai Science and Technology Committee, Bio-Pharma division.
In 2014, CRO for Biological analysis and Characterization of Macromolecular drugs was awarded by Shanghai government, Innovation Funds for Start-up.

Served for Amgen, Novartis, J&J, GSK, LifeTech, Team members from Mab-Venture management have over 15 years experiences in biological R&D and management. Also We have over 10 years experiences in CRO services and Customer Management, leaded R&D of 17 antibodies projects both in domestic and abroad.

George Wang, Ph.D.

Founder and CEO

Dr. Wang has over 21 years' experience in research, selection and development of biologics. As the visionary leader of Mab-Venture, his goal is to "Provide the domestic and international biopharma community with high quality biologics through innovative technology platforms".

Prior to the foundation of Mab-Venture, he participated in the establishment of WuXi Biologics, a subsidiary of WuXi AppTec, and Genor Biopharma, a leading mAb company. As the leader of product development and quality management for Genor, he completed integrated pre-clinical research and development for more than 10 Biologics. Many members from his team are currently working as leaders in process development, quality or project management in renowned domestic biopharmaceutical companies. Under his lead, the Herceptin biosimilar antibody drug, which was submitted for IND application in 2011, obtained approval for clinical trials in 2013, and currently is in Phase III studies. Before returning to China, Dr. Wang worked in several global Fortune 500 companies in the United States including, J&J, Novartis and Amgen.

Dr. Wang obtained his Ph.D. from Senfang Sui's laboratory, Tsinghua University in 1999. He completed his postdoctoral research at School of Medicine of Johns Hopkins University in USA in 2002.

JunYi Ye, Ph.D.

Senior Vice President

He graduated from yangming university in Taiwan and established the first private clinical laboratory animal institution in Taiwan. Taipei rongmin general hospital for 7 years, specialized in cancer cell immunotherapy. Lead Taiwan BE company two laboratories within three years, obtain OECD and TFDA GLP certification, and Malaysia BE center certification. Xiamen double hundred talents were selected in the seventh batch.

Current biomedical TSQA quality assurance association, deputy director of Taiwan, TFDA GLP laboratory, the director of audit, the OECD's excellent laboratory operations (GLP) national compliance monitoring system registry review committee, Taipei veterans general hospital IACUC committee member, Asia QA BBS AQAF founding member representatives.

Qingqing Chen, Ph.D.

Vice President

Dr. Chen has over 20 years' experiences in pharmaceutical industry, especially more than 10 years in biologics R&D and production. He is proficient in China GMP, and familiar with cGMP. He is also professional in technology transfer from lab scale to GMP manufacturing scale. He is good at downstream and formulation/fill-finish production based on expression systems of prokaryotic and eukaryotic.

Dr. Chen got his both bachelor's and master's degree in Biology at Nanjing University , and then earned Ph.D. at Zhejiang University in 2007 .

Yujuan La, Ph.D.

Vice President,Marketing and Business Department

Dr. La is mainly responsible for project management, business relationship, marketing, Intellectual Property management and customer services. With over 15 years R&D achievements in both academic and biomedical industry, Dr. La has led various CMC development programs, more specifically, in up- and down-stream process development, pilot manufacture scaling-up, quality assurance management, IND document preparation and filing etc.

She has played the major role in almost every step of entire therapeutic monoclonal antibody developments, with emphasis on manufacturing and QA with cGMPcompliances. Dr. La got her Ph.D. from Shanghai Jiao Tong University with excellencies in protein biochemistry and molecular biology.

Yi Wang

Senior Director, QA

Mr. Wang is the Senior Director in QA department in Mab-Venture. He has more than 20 years of experience in Biopharmaceutical industry. He has served as a Senior Director over 10 years in well-known pharmaceutical companies in China. Hundreds of products were released by him. He is expertized in establishing a quality system compliance with cGMP.

He got his master degree of Bioengineering in University of Science and Technology of China, and the other master degree of business administration in Donghua University. He is a biomedical senior engineer and has the license of pharmacist. Currently, he is the qualified person in Mab-Venture, focused on the quality assurance in process and products.

Pin Lv , Ph.D.

Executive Director

Dr. Lv expertized in biological analysis such as peptide mapping, disulfide bone analysis, N-Glycan, PTM identification and so on. He is responsible for macromolecular drug activity, product characterization and quality control.

Lead the QC Department staffs to conduct both internal and supplier audits, establish the quality standards for innovator and biosimilar drugs, perform analytical tests, verify and approve executed batch documents and certificates of analysis prior to release, and continuously improve the laboratory quality system. He has completed the clinical IND application of 10 monoclonal antibodies and published 5 papers and 11 patents. Ph.D. from East China University of Science and Technology.

Fusheng Dong

Process Principal

Mr. Dong has more than 10 years of experience in drug development, production and technology transfer of biological products. He has served as the person in charge of cell manufacture platform in Jinlin Maifeng, Changchun BCTH, Shanghai Jingze and other biological pharmaceutical companies. He is good at building and developing lab-scale, pilot-scale and manufacture GMP platforms.

With the ability of organizing and coordinating internally and externally, Mr. Dong expertized in process development and technology transferring including the related analytical method verification of production process and etc. for biologic products, especially for monoclonal antibodies and fusion proteins.

Dai Feiyi

Financial Director

Ms. Dai Feiyi is currently the Financial Director of Mab-Venture. She has more than 10 years' financial management experience in the fields of biomedicine, biological reagents, biological instruments and so on. Before joining Mab-Venture, Ms. Dai Feiyi ever worked in WuXi Apptec(ShangHai)Co.,Ltd, PRAJV and Gentimes Technology Co..

She has rich experience and good understanding of financial process management system, internal risk control system, financial plan analysis and comprehensive budget management solutions, group consolidation report, etc. She has been involved in the privatization of the US stock market (WuXi) , the related preparations for IPO to China market and IPO to Hongkong market.

She has led the design, construction of Group Financial Shared Service Center for WuXi Apptec, which has accomplished the full functional operation.
Copyright © 2019 2019 Mab-Venture Biopharm Co., Ltd. All Rights Reserved
Add:L3,NO.178 BAN XIA ROAD, PUDONG, SHANGHAI Tel:+86 21 5018 6802